- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT05572515
Исследование, сравнивающее монотерапию теклистамабом с помалидомидом, бортезомибом, дексаметазоном (PVd) или карфилзомибом, дексаметазоном (Kd) у участников с рецидивирующей или рефрактерной множественной миеломой (MajesTEC-9)
Рандомизированное исследование фазы 3, сравнивающее монотерапию теклистамабом с помалидомидом, бортезомибом, дексаметазоном (PVd) или карфилзомибом, дексаметазоном (Kd) у участников с рецидивирующей или рефрактерной множественной миеломой, которые получили от 1 до 3 предшествующих линий терапии, включая моноклональное антитело против CD38 и леналидомид
The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or refractory multiple myeloma.
Обзор исследования
Статус
Условия
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 3
Расширенный доступ
Контакты и местонахождение
Места учебы
-
-
-
Blacktown, Австралия, 2148
- Blacktown Hospital
-
Fitzroy, Австралия, 3065
- St Vincents Hospital Melbourne
-
Melbourne, Австралия, 3128
- Box Hill Hospital
-
Murdoch, Австралия, 6150
- Fiona Stanley Hospital
-
Nedlands, Австралия, 6009
- Sir Charles Gairdner Hospital
-
-
-
-
-
Salzburg, Австрия, 5020
- LKH - Universitätsklinikum der PMU Salzburg
-
Vienna, Австрия, A-1090
- Medical University Vienna MUV
-
-
-
-
-
Brasschaat, Бельгия, 2930
- Algemeen Ziekenhuis Klina
-
Haine-St-Paul, Бельгия, 7100
- Jolimont
-
Kortrijk, Бельгия, 8500
- Az Groeninge
-
Leuven, Бельгия, 3000
- Universitair Ziekenhuis Gasthuisberg
-
Liège, Бельгия, 4000
- CHR de la Citadelle
-
-
-
-
-
Brasília, Бразилия, 70390-140
- Hospitais Integradaos da Gavea S/A - DF Star
-
Caxias do Sul, Бразилия, 95070 560
- Fundacao Universidade de Caxias do Sul
-
Curitiba, Бразилия, 81520-060
- Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer
-
Joinville, Бразилия, 89201-260
- Instituto Joinvilense de Hematologia e Oncologia Ltda Centro de Hematologia e Oncologia
-
Natal, Бразилия, 59062 000
- Liga Norte Riograndense Contra O Cancer
-
Niterói, Бразилия, 24020-073
- Complexo Hospitalar de Niteroi
-
Rio de Janeiro, Бразилия, 22775-001
- Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)
-
Salvador, Бразилия, 41253-190
- IDOR - Regional Bahia
-
São José do Rio Preto, Бразилия, 15090-000
- Funfarme Sjrp
-
São Paulo, Бразилия, 05652-900
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
São Paulo, Бразилия, 01323-001
- Hospital Alemao Oswaldo Cruz
-
São Paulo, Бразилия, 01509 900
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo, Бразилия, 01308-901
- Sociedade Beneficente de Senhoras Hospital Sirio Libanes
-
São Paulo, Бразилия, 04537 081
- Clinica Medica Sao Germano LTDA
-
São Paulo, Бразилия, 01401 002
- IDOR - Regional Sao Paulo
-
São Paulo, Бразилия, 01321-001
- Real e Benemérita Associação Portuguesa de Beneficência
-
-
-
-
-
Cottbus, Германия, 03048
- Medizinische Universitat Lausitz Carl Thiem
-
Dresden, Германия, 01307
- Universitatsklinikum Carl Gustav Carus Dresden
-
Greifswald, Германия, 17475
- Universitätsmedizin Greifswald
-
Hamburg, Германия, 22763
- Asklepios Klinik Altona
-
Heidelberg, Германия, 69120
- Universitaetsklinikum Heidelberg
-
Marburg, Германия, 35043
- Universitaetsklinikum Giessen und Marburg GmbH
-
Tübingen, Германия, 72076
- Universitatsklinikum Tubingen
-
Ulm, Германия, 89070
- Universitatsklinikum Ulm
-
Zwickau, Германия, 08060
- Heinrich-Braun-Klinikum gGmbH
-
-
-
-
-
Athens Attica, Греция, 115 28
- Alexandra General Hospital of Athens
-
Pátrai, Греция, 263 35
- Agios Andreas General Hospital of Patra
-
Thessaloniki, Греция, 570 10
- G Papanikolaou Hospital of Thessaloniki
-
-
-
-
-
Aalborg, Дания, 9000
- Aalborg University Hospital
-
Aarhus, Дания, 8200
- Aarhus University Hospital
-
Copenhagen, Дания, DK-2100
- Rigshospitalet
-
Herning, Дания, 7400
- Regionshospitalet Godstrup
-
Odense C, Дания, 5000
- Odense Universitetshospital
-
Vejle, Дания, 7100
- Vejle Sygehus
-
-
-
-
-
Hadera, Израиль, 3810101
- Hillel Yaffe Medical Center
-
Haifa, Израиль, 31048
- Bnai Zion Medical Center
-
Haifa, Израиль, 3436212
- Carmel Medical Center
-
Petah Tikva, Израиль, 49100
- Rabin Medical Center
-
Ramat Gan, Израиль, 52621
- Sheba Medical Center
-
Tel Aviv, Израиль, 64239
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Gūrgaon, Индия, 122002
- Fortis Memorial Research Institute
-
Jaipur, Индия, 302017
- Bhagwan Mahaveer Cancer Hospital & Research Centre
-
Pune, Индия, 411004
- Deenanath Mangeshkar Hospital and Research Centre
-
-
-
-
-
Badalona, Испания, 08916
- Hosp. Univ. Germans Trias I Pujol
-
Jerez de la Frontera, Испания, 11407
- Hosp. de Jerez de La Frontera
-
L'Hospitalet de Llobregat, Испания, 08908
- Institut Catala d Oncologia L Hospitalet
-
León, Испания, 24008
- Hosp. de Leon
-
Madrid, Испания, 28041
- Hosp. Univ. 12 de Octubre
-
Madrid, Испания, 28034
- Hosp. Univ. Ramon Y Cajal
-
Madrid, Испания, 28031
- Hosp. Univ. Infanta Leonor
-
Murcia, Испания, 30008
- Hosp. Gral. Univ. J.M. Morales Meseguer
-
Oviedo, Испания, 33011
- Hospital Universitario Central de Asturias
-
Palma de Mallorca, Испания, 07198
- Hosp. Son Llatzer
-
Pontevedra, Испания, 36071
- Hosp. Montecelo
-
Pozuelo de Alarcón, Испания, 28223
- Hosp. Quiron Madrid Pozuelo
-
Valencia, Испания, 46026
- Hospital Universitari i Politecnic La Fe
-
-
-
-
-
Bologna, Италия, 40138
- A O U Sant Orsola Malpighi
-
Milan, Италия, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Palermo, Италия, 90127
- Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone
-
Pisa, Италия, 56126
- Ospedale Santa Chiara AO Universitaria Pisana
-
Reggio Emilia, Италия, 42123
- Arcispedale Santa Maria Nuova - IRCCS
-
Roma, Италия, 00128
- Campus Bio Medico di Roma
-
Siena, Италия, 53100
- A O Universitaria Senese Ospedale Santa Maria alle Scotte
-
Turin, Италия, 10126
- A.O.U. Citta della Salute e della Scienza di Torino - Presidio Molinette
-
Udine, Италия, 33100
- ASUI Santa Maria della Misericordia di Udine
-
Varese, Италия, 21100
- Ospedale di Circolo e Fondazione Macchi
-
-
-
-
Alberta
-
Calgary, Alberta, Канада, T2N 5G2
- Arthur J E Child Comprehensive Cancer Centre
-
-
New Brunswick
-
Saint John, New Brunswick, Канада, E2L 4L2
- Saint John Regional Hospital
-
-
Ontario
-
Brampton, Ontario, Канада, L6R 3J7
- Brampton Civic Hospital
-
Oshawa, Ontario, Канада, L1G2B9
- Lakeridge Health Oshawa
-
-
Quebec
-
Montreal, Quebec, Канада, H1T 2M4
- CIUSSS de l Est de l Ile de Montreal Installation Hopital Maisonneuve Rosemont
-
-
-
-
-
Beijing, Китай, 100020
- Beijing Chaoyang Hospital
-
Beijing, Китай, 102208
- BeiJing JiShuiTan Hospital
-
Changchun, Китай, 130021
- The First Bethune Hospital of Jilin University
-
Changsha, Китай, 410013
- The Third Xiangya Hospital, Central South University
-
Chengdu, Китай, 610032
- Sichuan Provincial Peoples Hospital
-
Chongqing, Китай, 400030
- Chongqing University Cancer Hospital
-
Fuzhou, Китай, 350001
- Fujian Meidical University Union Hospital
-
Guangzhou, Китай, 511363
- Sun Yat -Sen University Cancer Center
-
Hangzhou, Китай, 310003
- First affiliated Hospital of Zhejiang University
-
Hangzhou, Китай, 310003
- First affiliated Hospital of Zhejiang University 1
-
Harbin, Китай, 150000
- Harbin medical university cancer hospital
-
Nanchang, Китай, 330006
- The First Affiliated Hospital of NanChang University
-
Nanjing, Китай, 210008
- Nanjing Drum Tower Hospital
-
Nanning, Китай, 530021
- First Affiliated Hospital of Guangxi Medical University
-
Shanghai, Китай, 200434
- Shanghai Fourth People s Hospital
-
Shenyang, Китай, 110055
- Shengjing Hospital Of China Medical University
-
Shenzhen, Китай, 518025
- Shenzhen 2nd People's Hospital
-
Tianjin, Китай, 300060
- Tianjin Medical University Cancer Institute and Hospital
-
Tianjin, Китай, 301617
- Institute of Hematology and Blood Diseases Hospital
-
Wenzhou, Китай, 325000
- The First Affiliated Hospital of Wenzhou Medical University
-
Wuhan, Китай, 430023
- Wuhan Union Hospital
-
Wuxi, Китай, 214023
- Wuxi People s Hospital
-
Xi'an, Китай, 710004
- The Second Affiliated Hospital of Xi'an Jiaotong University
-
Zhengzhou, Китай, 450008
- Henan Cancer Hospital
-
-
-
-
-
George Town, Малайзия, 10450
- Hospital Pulau Pinang
-
Kota Kinabalu, Малайзия, 88200
- Hospital Queen Elizabeth
-
Kuala Lumpur, Малайзия, 59100
- University Malaya Medical Centre
-
Subang Jaya, Малайзия, 47500
- Subang Jaya Medical Centre
-
-
-
-
-
Amersfoort, Нидерланды, 3813 TZ
- Meander Medisch Centrum
-
Amsterdam, Нидерланды, 1081 HV
- VUMC Amsterdam
-
Groningen, Нидерланды, 9700 RB
- Universitair Medisch Centrum Groningen
-
Utrecht, Нидерланды, 3584 CX
- UMC Utrecht
-
-
-
-
-
Gdansk, Польша, 80 214
- Uniwersyteckie Centrum Kliniczne
-
Katowice, Польша, 40 519
- Pratia Onkologia Katowice
-
Kielce, Польша, 25 734
- Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach
-
Lublin, Польша, 20-081
- Uniwersytecki Szpital Kliniczny Nr 1 w Lublinie
-
-
-
-
-
Almada, Португалия, 2805-267
- Uls Almada Seixal - Hosp. Garcia de Orta
-
Braga, Португалия, 4710-243
- Uls Braga - Hosp. Braga
-
Lisbon, Португалия, 1400-038
- Champalimaud Foundation Champalimaud Centre
-
Porto, Португалия, 4200072
- Instituto Portugues de Oncologia
-
Vila Nova de Gaia, Португалия, 4434-502
- Uls Gaia Espinho
-
-
-
-
-
Aberdeen, Соединенное Королевство, AB25 2ZN
- Aberdeen Royal Infirmary
-
Birmingham, Соединенное Королевство, B15 2GW
- University Hospitals Birmingham NHS Foundation Trust
-
Colchester, Соединенное Королевство, CO4 5JL
- Colchester Hospital University NHS
-
Liverpool, Соединенное Королевство, L7 8YA
- The Clatterbridge Cancer Centre
-
London, Соединенное Королевство, SW17 0QT
- St Georges Hospital
-
London, Соединенное Королевство, SW10 9NH
- Chelsea And Westminster Hospital
-
Middlesbrough, Соединенное Королевство, Ts4 3Bw
- James Cook University Hospital
-
Norwich, Соединенное Королевство, NR4 7UY
- Norfolk and Norwich University Hospital
-
Staffordshire, Соединенное Королевство, ST4 6QG
- Royal Stoke University Hospital
-
-
-
-
Alaska
-
Anchorage, Alaska, Соединенные Штаты, 99508
- Alaska Oncology and Hematology LLC
-
-
Arizona
-
Gilbert, Arizona, Соединенные Штаты, 85234
- Banner MD Anderson Cancer Center
-
-
California
-
Berkeley, California, Соединенные Штаты, 94704
- Alta Bates Comprehensive Cancer Center
-
Long Beach, California, Соединенные Штаты, 90806
- MemorialCare Long Beach Medical Center
-
Orange, California, Соединенные Штаты, 92868
- University of California Irvine
-
Whittier, California, Соединенные Штаты, 90602
- PIH Health Hospital
-
-
Colorado
-
Aurora, Colorado, Соединенные Штаты, 80218
- Rocky Mountain Cancer Centers
-
-
Connecticut
-
Farmington, Connecticut, Соединенные Штаты, 06030
- University of Connecticut
-
-
Florida
-
Miami, Florida, Соединенные Штаты, 33136
- University of Miami Sylvester Cancer Center
-
Orlando, Florida, Соединенные Штаты, 32806
- Orlando Health Cancer Institute
-
Weston, Florida, Соединенные Штаты, 33331
- Cleveland Clinic Florida
-
-
Iowa
-
Waukee, Iowa, Соединенные Штаты, 50263
- Mission Cancer Blood
-
-
Louisiana
-
Metairie, Louisiana, Соединенные Штаты, 70006
- East Jefferson General Hospital Bone Marrow Transport Clinic
-
-
Maryland
-
Bethesda, Maryland, Соединенные Штаты, 20889
- Walter Reed National Military Medical Center
-
Silver Spring, Maryland, Соединенные Штаты, 20904
- Maryland Oncology Hematology P A
-
-
Massachusetts
-
Boston, Massachusetts, Соединенные Штаты, 02118
- Boston University Medical Center
-
-
Missouri
-
Chesterfield, Missouri, Соединенные Штаты, 63017
- Saint Lukes Hospital Saint Lukes Cancer Specialists
-
-
New Jersey
-
Camden, New Jersey, Соединенные Штаты, 08103
- Cooper Health System MD Anderson Cancer Center at Cooper
-
-
New York
-
New York, New York, Соединенные Штаты, 10032
- Herbert Irving Comprehensive Cancer Center Columbia University Medical Center
-
-
North Carolina
-
Durham, North Carolina, Соединенные Штаты, 27705
- Durham VAMC
-
-
Pennsylvania
-
Lancaster, Pennsylvania, Соединенные Штаты, 17601
- Penn Medicine Lancaster General Health
-
-
Tennessee
-
Nashville, Tennessee, Соединенные Штаты, 37203
- Tennessee Oncology
-
-
Texas
-
Fort Sam Houston, Texas, Соединенные Штаты, 78234
- Brooke Army Medical Center
-
Houston, Texas, Соединенные Штаты, 77030
- Baylor College of Medicine
-
Houston, Texas, Соединенные Штаты, 77030
- Michael E DeBakey VA Medical Center
-
Houston, Texas, Соединенные Штаты, 77054
- Harris Health Smith Clinic
-
-
Utah
-
Salt Lake City, Utah, Соединенные Штаты, 84106
- Utah Cancer Specialists
-
-
Virginia
-
Fort Belvoir, Virginia, Соединенные Штаты, 22060
- Alexander T. Augusta Military Medical Center
-
Norfolk, Virginia, Соединенные Штаты, 23502
- Virginia Oncology Associates
-
-
Washington
-
Tacoma, Washington, Соединенные Штаты, 98405
- NorthWest Medical Specialties, PLLC
-
-
-
-
-
Ankara, Турция (Туркие), 06200
- Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital
-
Ankara, Турция (Туркие), 06680
- Liv Hospital Ankara
-
Ankara, Турция (Туркие), 06620
- Ankara University Medical Faculty
-
Ankara, Турция (Туркие), 06010
- Ankara Gulhane Training and Research Hospital
-
Antalya, Турция (Туркие), 07100
- Antalya Training And Research Hospital
-
Denizli, Турция (Туркие), 20070
- Pamukkale University Medical Faculty
-
Istanbul, Турция (Туркие), 34214
- Medipol Mega Universite Hastanesi
-
Samsun, Турция (Туркие), 55280
- Ondokuz Mayis University
-
-
-
-
-
Amiens, Франция, 80000
- CHU Amiens - Hopital Sud
-
Caen, Франция, 14000
- Hôpital Côte de Nacre
-
Grenoble, Франция, 38700
- CHU Grenoble
-
Le Mans, Франция, 72037
- Centre Hospitalier du Mans
-
Lille, Франция, 59020
- Hopital Saint Vincent de Paul
-
Montpellier, Франция, 34295 cede
- CHU de Montpellier Hopital Saint Eloi
-
Nantes, Франция, 44000
- CHU Nantes
-
Paris, Франция, 75743
- Hopital Necker Enfants Malades
-
Paris, Франция, 75012
- Hopital Saint-Antoine
-
Paris, Франция, 75013
- Hopital de la Pitie Salpetriere
-
Toulouse, Франция, 31100
- Institut Universitaire du Cancer Toulouse Oncopole
-
Vandœuvre-lès-Nancy, Франция, 54500
- CHU de Nancy - Hopital de Brabois
-
-
-
-
-
Brno, Чехия, 625 00
- Fakultni nemocnice Brno
-
Olomouc, Чехия, 779 00
- Fakultni nemocnice Olomouc
-
Ostrava - Poruba, Чехия, 708 52
- Fakultni Nemocnice Ostrava
-
Prague, Чехия, 128 08
- Vseobecna fakultni nemocnice v Praze
-
-
-
-
-
Falun, Швеция, 791 82
- Falu Lasarett Medicinkliniken Falun
-
Helsingborg, Швеция, 25287
- Helsingborgs lasarett
-
Uppsala, Швеция, 751 85
- Akademiska Sjukhuset
-
-
-
-
-
Bunkyō City, Япония, 113 8519
- Institute of Science Tokyo Hospital
-
Chiba, Япония, 260-8717
- Chiba Cancer Center
-
Gifu, Япония, 503-8502
- Ogaki Municipal Hospital
-
Gunma, Япония, 377-0280
- National Hospital Organization Shibukawa Medical Center
-
Hirakata, Япония, 573 1191
- Kansai Medical University Hospital
-
Hitachi, Япония, 317-0077
- Hitachi General Hospital
-
Iruma-gun, Япония, 350-0495
- Saitama Medical University Hospital
-
Kamogawa, Япония, 296-8602
- Kameda Medical Center
-
Kashiwa, Япония, 277 8577
- National Cancer Center Hospital East
-
Kurashiki, Япония, 710-8602
- Kurashiki Central Hospital
-
Matsuyama, Япония, 790-8524
- Matsuyama Red Cross Hospital
-
Nagakute, Япония, 480-1195
- Aichi Medical University Hospital
-
Nagasaki, Япония, 852-8511
- JRC Nagasaki Genbaku Hospital
-
Niigata, Япония, 951 8520
- Niigata University Medical And Dental Hospital
-
Okayama, Япония, 701-1192
- National Hospital Organization Okayama Medical Center
-
Osaka, Япония, 545 8586
- Osaka Metropolitan University Hospital
-
Sapporo, Япония, 060-8648
- Hokkaido University Hospital
-
Tokyo, Япония, 113-0033
- Juntendo University Hospital
-
Tokyo, Япония, 135 8550
- The Cancer Institute Hospital of JFCR
-
Yamagata, Япония, 990 2331
- Yamagata University Hospital
-
Yamanashi, Япония, 400-8506
- Yamanashi Prefectural Central Hospital
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Documented diagnosis of multiple myeloma as defined by the criteria below: (a)Multiple myeloma diagnosis according to International Myeloma Working Group (IMWG) diagnostic criteria (b) Measurable disease at screening as defined by any of the following: (1) Serum M-protein level greater than or equal to (>=)0.5 grams per deciliter (g/dL) (central laboratory); or (2) Urine M-protein level >=200 milligrams (mg)/24 hours (central laboratory); or (3) Serum immunoglobulin free light chain >=10 milligrams per deciliter (mg/dL) (central laboratory) and abnormal serum immunoglobulin kappa lambda free light chain ratio
- Received 1 to 3 prior lines of antimyeloma therapy including a minimum of 2 consecutive cycles of an anti- cluster of differentiation 38 (CD38) monoclonal antibody at the approved dosing regimen in any prior line and 2 consecutive cycles of lenalidomide in any prior line
- Documented evidence of progressive disease or failure to achieve a response to last line of therapy based on investigator's determination of response by International myeloma working group (IMWG) criteria
- Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
- A female participant must agree not to be pregnant, breast-feeding, or plan to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment
- Must be willing and able to adhere to the lifestyle restrictions specified in this protocol
Exclusion Criteria:
- Received any prior B cell maturation antigen (BCMA)-directed therapy
- A participant is not eligible to receive PVd as control therapy if any of the following are present: (1) Received prior pomalidomide therapy, (2) Does not meet criteria for bortezomib retreatment (3) Contraindications or life-threatening allergies, hypersensitivity, or intolerance to pomalidomide or bortezomib, (4) Grade 1 peripheral neuropathy with pain or Grade greater than or equal to (>=) 2 peripheral neuropathy as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0, (5) Received a strong cytochrome P (CYP) 3A4 inducer within 5 half-lives prior to randomization; A participant is not eligible to receive Kd as control therapy if any of the following are present:(1) Received prior carfilzomib therapy, (2) Uncontrolled hypertension, defined as an average systolic blood pressure greater than (>)159 millimeters of mercury (mmHg) or diastolic blood pressure >99 mmHg despite optimal treatment (3) Grade 2 peripheral neuropathy with pain or Grade >=3 peripheral neuropathy as defined by NCI-CTCAE Version 5.0, (4) Contraindications or life-threatening allergies, hypersensitivity, or intolerance to carfilzomib (intolerance defined as prior therapy discontinued due to any adverse event [AE] related to carfilzomib)
- Received a maximum cumulative dose of corticosteroids of >=140 mg of prednisone or equivalent within 14 days prior to randomization
- Received a live, attenuated vaccine within 4 weeks before randomization
- Central nervous system (CNS) involvement or clinical signs of meningeal involvement of multiple myeloma
- Plasma cell leukemia at the time of screening, Waldenstrom's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, M-protein (POEMS) syndrome and skin changes, or primary amyloid light chain amyloidosis
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Teclistamab
Participants will receive teclistamab monotherapy in Part 1 and an alternative dosing regimen of teclistamab in Part 2. Participants who are still receiving the treatment and benefiting from it may enter the long-term extension (LTE) and drug access (DA)-LTE Phases to continue their current treatment until end of the study. |
Teclistamab will be administered subcutaneously.
Другие имена:
|
|
Экспериментальный: Pomalidomide, Bortezomib and Dexamethasone (PVd) or Carfilzomib and Dexamethasone (Kd)
Participants will receive either PVd or Kd based on principal investigator's choice during Part 1 of the study. Participants who are still receiving the treatment and benefiting from it may enter the LTE and DA-LTE Phases to continue their current treatment until end of the study. |
Pomalidomide will be administered orally. Carfilzomib will be administered intravenously. Bortezomib will be administered subcutaneously. Dexamethasone will be administered orally in PVd and intravenously or orally in Kd. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Part 1: Progression-free Survival (PFS)
Временное ограничение: Up to 9 years
|
PFS is defined as the time from the date of randomization to the date of first documented disease progression, as defined in the International myeloma working group (IMWG) 2016 response criteria, or death due to any cause, whichever occurs first. |
Up to 9 years
|
|
Part 2: Number of Participants Reporting Cytokine Release Syndrome (CRS) Cases by Severity
Временное ограничение: Up to 9 years
|
Severity for CRS will be graded as follows: Grade 1: Fever (Temperature greater than or equal to [>=] 38°C); Grade 2: Fever (Temperature >=38°C) with either: hypotension and/or hypoxia requiring low-flow nasal cannula or blow-by; Grade 3: Fever (Temperature >=38°C) with either: hypotension and/or hypoxia requiring high-flow nasal cannula, facemask, nonrebreather mask, or Venturi mask; Grade 4: Fever (Temperature >=38°C) with either: hypotension requiring multiple vasopressors (excluding vasopressin), and/or hypoxia requiring positive pressure and Grade 5: Death. |
Up to 9 years
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Part 1 and 2: Overall Response (Partial Response [PR] or Better)
Временное ограничение: Up to 9 years
|
Overall response (PR or better) is defined as participants who have a PR or better prior to subsequent antimyeloma therapy in accordance with the IMWG 2016 criteria. |
Up to 9 years
|
|
Part 1 and 2: Very Good Partial Response (VGPR) or Better Response
Временное ограничение: Up to 9 years
|
VGPR or better (Stringent Complete Response [sCR]+Complete Response [CR]+VGPR) is defined as participants who achieve a VGPR or better response prior to subsequent antimyeloma therapy in accordance with the IMWG 2016 criteria. |
Up to 9 years
|
|
Part 1 and 2: Complete Response (CR) or Better Response
Временное ограничение: Up to 9 years
|
CR or better response is defined as participants who achieve a CR or better response prior to subsequent antimyeloma therapy in accordance with the IMWG 2016 criteria. |
Up to 9 years
|
|
Part 1: Duration of Response (DOR)
Временное ограничение: Up to 9 years
|
DOR is defined as the time interval between the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease according to the IMWG 2016 response criteria or death due to any cause, whichever occurs first. |
Up to 9 years
|
|
Part 1: Time to Next Treatment (TTNT)
Временное ограничение: Up to 9 years
|
TTNT is defined as the time from randomization to the start of subsequent antimyeloma treatment. |
Up to 9 years
|
|
Part 1: Progression-free Survival on Next-line Therapy (PFS2)
Временное ограничение: Up to 9 years
|
PFS2 is defined as the time interval between the date of randomization and date of event, which is defined as progressive disease as assessed by investigator on the first subsequent line of antimyeloma therapy, or death from any cause, whichever occurs first. |
Up to 9 years
|
|
Part 1: Overall Survival (OS)
Временное ограничение: Up to 9 years
|
OS is defined as the time from the date of randomization to the date of the participant's death due to any cause. |
Up to 9 years
|
|
Part 1 and 2: Number of Participants with Adverse Events (AEs) by Severity
Временное ограничение: Up to 9 years
|
Number of participants with AEs by Severity will be reported. |
Up to 9 years
|
|
Part 1 and 2: Number of Participants with Serious Adverse Events (SAEs) by Severity
Временное ограничение: Up to 9 years
|
Number of participants with SAEs by Severity will be reported. |
Up to 9 years
|
|
Part 1 and 2: Number of Participants with Abnormal Laboratory Results
Временное ограничение: Up to 9 years
|
Number of participants with abnormal laboratory results (such as hematology and chemistry) will be reported. |
Up to 9 years
|
|
Part 1 and 2: Serum Concentrations of Teclistamab
Временное ограничение: Up to 9 years
|
Serum concentrations of teclistamab will be reported. |
Up to 9 years
|
|
Part 1 and 2: Number of Participants with Anti-drug Antibodies (ADAs) to Teclistamab
Временное ограничение: Up to 9 years
|
Number of participants with ADAs to teclistamab will be reported. |
Up to 9 years
|
|
Part 1: Change from Baseline in Symptoms, Functioning, and Overall Health-related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30)
Временное ограничение: Baseline up to 9 years
|
Change from baseline in symptoms, functioning, and overall HRQoL assessed by EORTC QLQ-C30 score version 3 will be reported. The EORTC- QLQ-C30 Version 3 includes 30 items that make up 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea/vomiting), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The item and scale scores are transformed to a 0 to 100 scale. A high scale score represents a higher response level. Thus, a high score for a functional scale represents a high/healthy level of functioning and a high score for the global health status represents high HRQoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems. |
Baseline up to 9 years
|
|
Part 1: Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) Scale Score
Временное ограничение: Baseline up to 9 years
|
Change from baseline in symptoms, functioning, and overall HRQoL assessed by MySIm-Q will be reported. The MySIm-Q is a disease-specific PRO assessment complementary to the EORTC-QLQ-C30. It includes 17 items resulting in a symptom subscale and an impact subscale. The recall period is the "past 7 days", and responses are reported on a 5-point verbal rating scale. |
Baseline up to 9 years
|
|
Part 1: Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Временное ограничение: Baseline up to 9 years
|
Change from baseline in symptoms, functioning, and overall HRQoL assessed by PRO-CTCAE will be reported. The National Cancer Institute's (NCI's) PRO-CTCAE is an item library of common adverse events experienced by people with cancer that are appropriate for self-reporting of treatment tolerability. Each symptom selected for inclusion can be rated by up to 3 attributes characterizing the presence/frequency, severity, and/or interference of the AEs. It ranges from 0 to 4 with higher scores indicating higher frequency or greater severity/impact. |
Baseline up to 9 years
|
|
Part 1: Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L)
Временное ограничение: Baseline up to 9 years
|
Change from baseline in symptoms, functioning, and overall HRQoL assessed by EQ-5D-5L will be reported. The EQ-5D-5L is a generic measure of health status. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). |
Baseline up to 9 years
|
|
Part 1: Time to Worsening in Symptoms, Functioning, and Overall HRQoL
Временное ограничение: Up to 9 years
|
Time to worsening in symptoms, functioning, and overall HRQoL will be measured as the interval from the date of randomization to the start date of meaningful change. |
Up to 9 years
|
|
Part 1: PFS in Participants in High-risk Molecular Features
Временное ограничение: Up to 9 years
|
PFS in participants in high-risk molecular features will be reported. PFS is defined as the time from the date of randomization to the date of first documented disease progression, as defined in the IMWG 2016 response criteria, or death due to any cause, whichever occurs first. |
Up to 9 years
|
|
Part 1: Depth of Response in Participants in High-risk Molecular Features
Временное ограничение: Up to 9 years
|
Depth of response in participants in high-risk molecular features will be reported. |
Up to 9 years
|
Соавторы и исследователи
Следователи
- Директор по исследованиям: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Сосудистые заболевания
- Сердечно-сосудистые заболевания
- Новообразования
- Заболевания иммунной системы
- Новообразования по гистологическому типу
- Гематологические заболевания
- Лимфопролиферативные заболевания
- Иммунопролиферативные заболевания
- Новообразования, Плазматические клетки
- Нарушения гемостаза
- Парапротеинемии
- Нарушения белков крови
- Геморрагические расстройства
- Гемики и лимфатические заболевания
- Множественная миелома
- Органические химические вещества
- Гетероциклические соединения, 1-кольцо
- Гетероциклические соединения
- Полициклические соединения
- Неорганические химические вещества
- Беременные
- Беременные
- Стероиды
- Соединения слитого кольца
- Стероиды, фторированные
- Bergyadienetriols
- Бороновые кислоты
- Кислоты, некарбоновая
- Кислоты
- Бор соединения
- Пиразины
- Бортезомиб
- Дексаметазон
- Карфилзомиб
- Помалидомид
Другие идентификационные номера исследования
- CR109244
- 64007957MMY3006 (Другой идентификатор: Janssen Research & Development, LLC)
- 2022-000928-37 (Номер EudraCT)
- 2023-503444-13-00 (Идентификатор реестра: EUCT number)
- 2023 (Грант/контракт NIH США)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .